Skip to content

Rallybio

  • About Us
    • Company Overview
    • Team
    • Board of Directors
  • Our Science
    • Our Pipeline
    • Our Process
  • Newsroom
  • Investors
  • Contact

RLYB115

  • About Us
    • Company Overview
    • Team
    • Board of Directors
  • Our Science
    • Our Pipeline
    • Our Process
  • Newsroom
  • Investors
  • Contact

Stage:Preclinical
Indication:Immuno-inflammation
Therapeutic Modality:Protein
Mechanism of Action:Undisclosed

RLYB115 is an undisclosed product candidate in development for the treatment of patients with severe, rare immuno-inflammatory diseases.

Rallybio

234 Church Street
Suite 1020
New Haven, CT 06510

203-859-3820

  • Rallybio on Linkedin
  • Rallybio Newsroom

© 2021 Rallybio

  • |Terms of Use
  • |Privacy Policy